BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 25633483)

  • 1. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
    de Vries CR; Monken CE; Lattime EC
    Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
    Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
    Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
    McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
    J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen.
    Yang AS; Monken CE; Lattime EC
    Cancer Res; 2003 Oct; 63(20):6956-61. PubMed ID: 14583497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
    Machiels JP; Reilly RT; Emens LA; Ercolini AM; Lei RY; Weintraub D; Okoye FI; Jaffee EM
    Cancer Res; 2001 May; 61(9):3689-97. PubMed ID: 11325840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.
    Masuelli L; Marzocchella L; Focaccetti C; Lista F; Nardi A; Scardino A; Mattei M; Turriziani M; Modesti M; Forni G; Schlom J; Modesti A; Bei R
    Cancer Immunol Immunother; 2010 Aug; 59(8):1247-58. PubMed ID: 20364378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking.
    Tan Z; Chiu MS; Yue M; Kwok HY; Tse MH; Wen Y; Chen B; Yang D; Zhou D; Song YQ; Man K; Chen Z
    J Leukoc Biol; 2024 Mar; 115(4):633-646. PubMed ID: 38066571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF.
    Choi KJ; Zhang SN; Choi IK; Kim JS; Yun CO
    Gene Ther; 2012 Jul; 19(7):711-23. PubMed ID: 21993173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
    Murata S; Ladle BH; Kim PS; Lutz ER; Wolpoe ME; Ivie SE; Smith HM; Armstrong TD; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2006 Jan; 176(2):974-83. PubMed ID: 16393983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
    Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
    Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.
    Nemeckova S; Smahel M; Hainz P; Mackova J; Zurkova K; Gabriel P; Indrova M; Kutinova L
    Neoplasma; 2007; 54(4):326-33. PubMed ID: 17822323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.
    Abe F; Dafferner AJ; Donkor M; Westphal SN; Scholar EM; Solheim JC; Singh RK; Hoke TA; Talmadge JE
    Cancer Immunol Immunother; 2010 Jan; 59(1):47-62. PubMed ID: 19449184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu.
    Bergman I; Griffin JA; Gao Y; Whitaker-Dowling P
    Int J Cancer; 2007 Jul; 121(2):425-30. PubMed ID: 17354238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.
    Inoue T; Byrne T; Inoue M; Tait ME; Wall P; Wang A; Dermyer MR; Laklai H; Binder JJ; Lees C; Hollingsworth R; Maruri-Avidal L; Kirn DH; McDonald DM
    Mol Cancer Ther; 2021 Aug; 20(8):1481-1494. PubMed ID: 34045231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.